Ardent Health Q4 adjusted EBITDA beats estimates, driven by expense optimization

Ardent Health

04/03/2026 21:40

Overview

Healthcare provider's Q4 revenue decreased 0.1% yr/yr, missing analyst expectations

Adjusted EBITDA for Q4 beat analyst expectations, driven by expense optimization

Company's IMPACT program improved SWB expenses and stabilized payor dynamics

Outlook

Ardent Health expects 2026 revenue between $6.4 bln and $6.7 bln

Company forecasts 2026 adjusted EBITDA of $485 mln to $535 mln

Result Drivers

ADMISSIONS GROWTH - Admissions increased 1.5% driven by strong inpatient surgery growth

INPATIENT SURGERY GROWTH - Inpatient surgeries grew 3.9% year-over-year, offsetting outpatient surgery decline

Company press release: ID:nBw9rtFswa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$1.61 bln
$1.63 bln (11 Analysts)
Q4 EPS
$0.32
Q4 Net Income
$74.26 mln
Q4 Adjusted EBITDA
Beat
$134 mln
$130.47 mln (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Ardent Health Inc is $14.00, about 48.8% above its March 3 closing price of $9.41

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)